Modification of the three-dimensional method for the detection of AmpC β-lactamase in Enterobacter spp. and Escherichia coli | ||
Journal of University of Anbar for Pure Science | ||
Article 3, Volume 4, Issue 2, August 2010, Pages 8-12 PDF (389.95 K) | ||
Document Type: Research Paper | ||
DOI: 10.37652/juaps.2010.43915 | ||
Author | ||
Sirwa Mustafa mohammed | ||
University of Sulaimani - College of Education | ||
Abstract | ||
Laboratory failure in the detection of Ambler class C (AmpC) β-lactamases in Gram negative bacteria represents a major cause for its spreading and may be associated with low therapeutic outcome. The aim of this study was to develop a more practical and simplified laboratory technique by modifying the three-dimensional method for the detection of AmpC β-lactamase in Enterobacter spp and Escherichia coli. Twenty eight clinical isolates including 11 isolates of Enterobacter cloacae, 2 isolates of Enterobacter aerogenes and 15 isolates of Escherichia coli tested by standard disk diffusion methods against cefoxitin 30μg disk as primary screening for detection of AmpC β-lactamase then all isolates tested for its production of AmpC β-lactamase by a modified three dimensional method (3DM) with cefoxitin. Escherichia coli ATCC 25922 was used as negative controls (non-AmpC producer). In addition, the susceptibility test of 15 Escherichia coli isolates was performed against selected betalactam antibiotics. All Enterobacter isolates and one Escherichia coli isolate showed resistance to cefoxitin and showed positive result with the modified 3DM (M3DM) by enhanced growth of the surface organism (E. coli ATCC 25922) at the point where the slit intersected the zone of inhibition, while all cefoxitin-susceptible E. coli isolates showed M3DM negative results. A high percentage of Escherichia coli isolates were non-susceptible to β-lactam antibiotics used but they showed good susceptibility to imipenem (100%).The M3DM provides a cost-effective alternative for AmpC β-lactamase testing in clinical microbiology laboratories, thus negating the need for tedious bacterial lysis procedures required in the 3DM | ||
Keywords | ||
Detection AmpC; lactamase Enterobacter spp Escherichia coli | ||
References | ||
1- Livermore, D. M. (1995). β-lactamase in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.
2- Coudron, P.E., Moland, E.S., and Thomson,K.S. (2000). Occurrence and detection of AmpC β-lactamase among Esherichia coli, Klebsiella pneumoniae and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol. 38:1791-1796.
3- Moland, E.S., Black, J.A., Ourda, J., Reisbig, M.D., Hanson, N.D., and Thomson, K.S. (2002). Occurrence of newer ß-lactamase in Klebsiella pneumnoiae isolates from 24 U.S hospital. Antimicrob. Agents Chemother. 46:3837-3842.
4- Black, J.K., Moland, E. S., and Thomson, K.S. (2005). AmpC Disk Test for Detection of Plasmid-Mediated AmpC ß-Lactamases in Enterobacteriaceae Lacking Chromosomal AmpC β-Lactamases. J of Clin Microbiol .43 (7): 3110-3113.
5- Fridkin, S.K., Welbel, S.F., and Weinstein, R.A. (1997). Magnitude and prevention of nosocomial infections in the intensive care unit. Infect Dis Clin North Am. 1997; 11:479-496.
6- Medeiros AA. (1997) Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis. 24 (Suppl 1): S19-45.
7- Kaye, K.S., Fraimow, H.S., and Abrutyn, E. (2000). pathogens resistant to antimicrobial agents Epidemiology, Molecular Mechanisms, and Clinical Management. Infect Dis Clin of North America. 14(2): 293-319.
8. Schwaber, M.J., Graham, C.S., Sand, S.B.E., Gold, H.S., and Carmeli, Y. (2003). Treatment with a broad–spectrum cephalosporin versus piperacillin-resistant Enterobacter species. Antimicrob Agents and Chemother. 1882-1886.
9- Pitout, J.D.D., Gergson, D.B., Church, D.L., and Lapland, K.B. (2007). Population-based Laboratory Surveillance for AmpC β-Lactamase–producing Escherichia coli,Calgary. Emerg Infect Dis.13 (3).
10- Nasim, K., Elsayed, E., Pitout, J.D.P., Conly, J., Church, D.L., and Gregson, D.B. (2004). New method for laboratory detection of AmpC β-lactamase in Esherichia coli and Klebsiella pneumoniae. J of Clin microbial. 42(10): 4799-4802.
11- Thomson, K.S. (2001). Controversies about extended-spectrum and AmpC β-Lactamase.CDC. 7:333-336.
12- Soussy, C.J., Carret, G., Cavallo, J.D., Chardon, H., Chidiac, C., Choutet, P., Courvalin, P., Dabernat, H., Drugeon, H., Dubreuil, L., Goldstein, F., Jarlier, V., Leclercq, R., Nicolas-Chanoine, M.H., Philippon, A., Quentin, C., Rouveix, B., and Sirot., J. (2001). Comité de l'Antibiogramme de la Société Française de Microbiologie. Communiqué. Pathol. Biol. 48:832-871.
13- Brown, R. and Poxton, I,R.(1996). Centrifuges, colorimeters and bacterial counts. In: Mackie and McCartney Practical Medical Microbiology. (eds Collee, J. G., Fraser, A.G., Marmion, B.P and Simmons, A.. P845-852. 14th ed. Churchill Livingstone, Singapore.
14- Bouza, E. and Cerenado, E. (2002). Klebseilla and Enterobacter: antibiotic resistance and treatment implications. Semin Respir Infect. 17(3): 215-230.
15- Kolar, M., Bardon, J.,Chroma, M.,Hricova, K.,Stosoval,T., Sauer,P., and Koukalova ,D.(2010). ESBL and AmpC beta-lactamase-producing Enterobacteriaceae in poultry in the Czech Republic. Veterinarni Medicina, 55 (3): 119–124
16- Livermore, D. M. (1998). β-lactamase-mediated resistance and opportunities for its control. J. of Antimicrob. Chemother. 41:25-41.
17- Nigel, P., Jevons, B.G., Andrews, A., Ang, L., and Fraise, A.P. (2005). Disc methods for detecting AmpC ß-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae. J. of Antimicrob. Chemother . 56(3):600-601.
18- Yagi, T., Wachino, J., Kurokawa, H., Suzuki, S., Yamane, K., Doi, Y., Shibata, N., Kato, H., Shibayama, K. and Arakawa, Y. (2005). Practical methods using boronic acid compounds for identification of class C β-lactamase producing Klebsiella pneumoniae and Escherichia coli. J of Clin Microbial. 43(6): 2551-2558. | ||
Statistics Article View: 180 PDF Download: 157 |